Ra Medical Systems - RMED Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ra Medical Systems in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RMED shares.
View RMED analyst ratings or view top-rated stocks.

1 brokers have issued 12 month price objectives for Ra Medical Systems' shares. Their RMED share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 6,493.4% from the stock's current price.
View analysts price targets for RMED or view top-rated stocks among Wall Street analysts.

Ra Medical Systems' stock was trading at $1.56 at the beginning of 2022. Since then, RMED shares have decreased by 88.3% and is now trading at $0.1820.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our RMED earnings forecast.

Ra Medical Systems, Inc. (NYSE:RMED) released its quarterly earnings results on Monday, May, 16th. The company reported ($0.27) EPS for the quarter. The firm had revenue of $0.01 million for the quarter. Ra Medical Systems had a negative trailing twelve-month return on equity of 152.46% and a negative net margin of 2,278.22%.

Ra Medical Systems shares reverse split on the morning of Tuesday, November 17th 2020. The 1-25 reverse split was announced on Monday, November 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Medical Systems investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Novan (NOVN), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL) and Zosano Pharma (ZSAN).

(RMED) raised $50 million in an IPO on Thursday, September 27th 2018. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and Cantor acted as the underwriters for the IPO and SunTrust Robinson Humphrey, Nomura and Maxim Group were co-managers.

Ra Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMED."

Shares of RMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RMED stock can currently be purchased for approximately $0.18.

Ra Medical Systems (NYSE:RMED) has a market capitalization of $5.88 million and generates $20,000.00 in revenue each year. The company earns $-25,070,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis.

Ra Medical Systems' mailing address is 2070 Las Palmas Drive, Carlsbad CA, 92011. The official website for the company is www.ramed.com. The company can be reached via phone at (760) 804-1648 or via email at jcain@lhai.com.